Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump

被引:106
作者
Pumbwe, L [1 ]
Piddock, LJV [1 ]
机构
[1] Univ Birmingham, Sch Med, Div Immun & Infect, Antimicrobial Agents Res Grp, Birmingham B15 2TT, W Midlands, England
关键词
efflux; Campylobacter multidrug efflux B; multiple antibiotic resistance; Campylobacter jejuni;
D O I
10.1016/S0378-1097(01)00532-8
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A multidrug efflux pump gene (cmeB) was identified from the published Campylobacter jejuni genome sequence. Secondary structural analysis showed that the gene encoded a protein belonging to the resistance nodulation cell division (RND) family of efflux transporters. The gene was inactivated by insertional mutagenesis. Compared with the wild-type strain (NCTC 11168), the resultant knockout strain (NCTC 11168-cmeB::kan(r)) displayed increased susceptibility to a range of antibiotics including (beta-lactams, fluoroquinolones, macrolides, chloramphenicol, tetracycline, ethidium bromide, the dye acridine orange and the detergent sodium dodecyl sulfate. Accumulation of ciprofloxacin was increased in the knockout mutant, but carbonyl cyanide m-chlorophenyl hydrazone, a proton motive force inhibitor, had less effect upon ciprofloxacin accumulation in the knockout mutant compared with NCTC 11168. These data show that the identified gene encodes an RND-type mufti-substrate efflux transporter, which contributes to intrinsic resistance to a range of structurally unrelated compounds in C jejuni. This efflux pump has been named CmeB Campylobacter Multidrug efflux. (C) 2002 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:185 / 189
页数:5
相关论文
共 25 条
[1]  
Aarestrup FM, 2001, VET RES, V32, P311, DOI 10.1051/vetres:2001127
[2]  
Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760
[3]   The structure and function of drug pumps [J].
Borges-Walmsley, MI ;
Walmsley, AR .
TRENDS IN MICROBIOLOGY, 2001, 9 (02) :71-79
[4]  
CHAVALOS E, 1995, ANTIMICROB AGENTS CH, V39, P2019
[5]   Quinolone and macrolide resistance in Campylobacter jejuni and C-coli:: Resistance mechanisms and trends in human isolates [J].
Engberg, J ;
Aarestrup, FM ;
Taylor, DE ;
Gerner-Smidt, P ;
Nachamkin, I .
EMERGING INFECTIOUS DISEASES, 2001, 7 (01) :24-34
[6]   MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa:: Identification of MexR binding sites in the mexA-mexR intergenic region [J].
Evans, K ;
Adewoye, L ;
Poole, K .
JOURNAL OF BACTERIOLOGY, 2001, 183 (03) :807-812
[7]   Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals [J].
Everett, MJ ;
Jin, YF ;
Ricci, V ;
Piddock, LJV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2380-2386
[8]   Ciprofloxacin resistant Campylobacter spp in humans: An epidemiological and laboratory study [J].
Gaunt, PN ;
Piddock, LJV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (04) :747-757
[9]   Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyr4 and parC [J].
Gibreel, A ;
Sjögren, E ;
Kaijser, B ;
Wretlind, B ;
Sköld, O .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3276-3278
[10]   Emerging mechanisms of fluoroquinolone resistance [J].
Hooper, DC .
EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :337-341